Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Degludec/Insulin Aspart vs Insulin Glargine in Japanese Patients with Type 2 Diabetes
NCT01272193Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2011
- Primary completion
- Sep 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of insulin degludec + insulin aspart in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Jan 2011; status: completed.
02
Drugs
insulin degludec + insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01272193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01272193.